Abstract: The present application relates to a medical light diffusion implant and, more specifically, to a functional implant to emit medical lights so as to induce rapid recovery after an implantation. According to the present invention, A medical light diffusion implant, comprising a socket including a space therein, capable of being fixed to a living body and a crown coupled with the socket so as to seal the socket, wherein the socket is transmittable by lights, and comprises a light source unit included at an inner space of the socket and the crown coupled to each other, to emit the lights.

Abstract: The present application relates to a medical light diffusion implant and, more specifically, to a functional implant to emit medical lights so as to induce rapid recovery after an implantation. According to the present invention, A medical light diffusion implant, comprising a socket including a space therein, capable of being fixed to a living body and a crown coupled with the socket so as to seal the socket, wherein the socket is transmittable by lights, and comprises a light source unit included at an inner space of the socket and the crown coupled to each other, to emit the lights.

Abstract: The present invention is directed to compounds of formula (I) that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. Wherein R3 is -alkylene-SO2NR5R6.

Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

Abstract: The present invention is directed to compounds of formula (I) that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. Wherein R3 is -alkylene-SO2NR5R6.

Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

Abstract: The present invention describes novel cyclic diol derivatives represented by formula I and II: ##STR1## in which Y represents O, S, SO, SO.sub.2, (CH.sub.2).sub.m wherein m is zero or an integer of 1 to 5, or NR.sup.a group wherein R.sup.a is hydrogen, lower alkyl, lower alkoxycarbonyl, aryl, arylalkyl or acyl;R.sup.1 represents an alkyl or alkylcarbamoyl group;R.sup.2 represents a group having formula T--(CH.sub.2).sub.n --V (X.sup.-)q, wherein T refers to a simple covalent bond, a CO, PO.sub.3.sup.-, C(O)O, or CONR.sup.b group wherein R.sup.b is hydrogen, lower alkyl or acyl;n refers to an integer of from 1 to 10;V represents either (i) the group indicated by formula --.sup.+ NR.sup.5 R.sup.6 R.sup.7 wherein R.sup.5, R.sup.6 and R.sup.7 stands for identical or different lower alkyl group, or two or three of R.sup.5, R.sup.6 and R.sup.7 taken together with the adjacent nitrogen form heterocyclic ammonio group, or (ii) the group indicated by the formula ##STR2## wherein R.sup.

Abstract: A scanning format conversion circuit for performing the mutual conversion between a progressive scanning format and a zig-zag scanning format to read or write N.times.N discrete cosine transform coefficients from or into a memory in a coding process or a decoding process of a video system. The scanning format conversion circuit comprises a pure logic circuit including an up/down counting circuit, a down counting circuit, first to third selection circuits, a comparison circuit, a phase change circuit, and an accumulation circuit. With this construction, the mutual conversion between the progressive scanning format and the zig-zag scanning format is performed on the basis of the rule between the input orders and the actual positions of the discrete cosine transform coefficients. Therefore, the scanning format conversion circuit is capable of simplifying the implementation of ASIC and performing the scanning format conversion operation regardless of a block size.

Abstract: An improved motion vector extractor comprising a first pixel delay element for delaying pixel data of the previous frame by a one pixel interval, a second pixel delay element for delaying the pixel data of the previous frame by a horizontal line interval of a seek block, a third pixel delay element for delaying the pixel data of the previous frame by a seek block horizontal line and one pixel interval, an interpolation circuit for combining the pixel data of the previous frame and the delayed pixel data of the previous frame from the first to third pixel delay elements to produce at least one interpolation pixel data positioned between adjacent ones thereof, a fourth pixel delay element for delaying pixel data of the present frame to produce rectangularly arranged pixel data of the present frame, a plurality of MAD detectors, each of the plurality of MAD detectors subtracting a corresponding one of the interpolation pixel data from the interpolation circuit from a corresponding one of the rectangularly arrang

Abstract: The Centralized Management System utilizing a Bus Interface Unit comprises a Computer (4z) installing an address Bus (4a), data Bus (4b), and control Bus (4c), a First-Level Station (4Q 1) communicating with the Computer (4z) as the First-Level Station (4Q 1) is connected to the buses (4a, 4b, 4c) of the Computer (4z), a plurality of second-level stations (4Q2, 4Q3, . . . , 4QM) communicating with the First-Level Station (4QI) as the second-level stations (4Q2, 4Q3, . . . , 4QM) are connected to the First-Level Station through a Multipoint Bus (4r). Therefore, the Centralized Management System is capable of communicating the Computer with the First-Level Station through a Dual Port RAM (Random Access Memory), intercommunicating a plurality of Second-Level Stations through a Multipoint Interface and Multipoint Bus, and controlling and managing several thousands of Terminals (for example, Public Telephones).

Abstract: A coin treatment apparatus is disclosed that includes structure for selecting the inserted coins based upon their size, in accordance with their specific currency units, and transferring the coins to a receiving space. Once in the receiving space, coins of the correct currency unit are moved to their respective receiving containers within a receiving box. Coins that are not of the correct currency unit are transferred to a separate receiving space and discharged from the apparatus.

Abstract: An optical system for a projector which is capable of compensating the keystoning. The system comprises a light source, a light condensing part, a projected object, an image projecting part for focusing and projecting the image on a screen, and an optical path diversifying mirror. The optical path diversifying mirror is arranged as inclined at 45.degree. angle of inclination with respect to the optical path of the light and also as being capable of parallel moving with the optical path toward or away from the projected object, thereby upwardly and downwardly projecting the image without occurrence of the keystoning on the screen. The present invention is applied for a three panel type of LCD projector comprising a plurality of projected objects, and an image projecting lens part for composing.

Abstract: A system for transdermally delivering a hydrophobic alkanol soluble active agent to the skin at a constant rate utilizing a lower alkanol penetration enhancer. The system comprises an overlying solvent reservoir containing a lower alkanol solvent and a drug compartment containing an active agent in aqueous alkanol. A one-way membrane is sandwiched between and divides the solvent reservoir from the drum compartment. The one-way membrane is permeable to the alkanol solvent and substantially impermeable to back flux of drug and water into the reservoir. An outer membrane permeable to the alkanol solvent and drug is attached to the outer surface of the drug compartment. Adhesive means is contained on the outer surface of this membrane for attaching the delivery system to the skin of a wearer. Alkanol from the reservoir permeates into the drug compartment and drug and alkanol pass through the outer membrane to the skin of the wearer for transdermal absorption.

Abstract: A benzoxazine or benzothiazine derivative of the formula (A), ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are the same or different and represent a hydrogen atom or a C.sub.1-4 alkyl group; or R.sub.1 and R.sub.2 can be joined together along with the imidazole ring to form a benzimidazole; X and Y are the same or different and represent an oxygen or sulfur atom; or a pharmaceutically acceptable salt thereof, exhibits an excellent inotropic effect and can be used as a cardiac stimulant.

Abstract: A stainless maraging steel and process having high strength, high toughness and high corrosion resistance. The alloy consists of from 8 to 12% by weight Cr, 7 to 12% by weight Ni, 2 to 6% by weight W, 0.1 to 0.5% by weight Al, 0.1 to 0.4% by weight Ti, and the balance iron.

Abstract: The present invention relates to novel cephalosporin compounds having high antimicrobial activity, which are shown by the formula(I), and to a process for preparing them ##STR1## wherein R.sup.1 is a hydrogen atom or an amino protecting group;R.sup.2 is acetoxy; andR.sup.3 is a hydrogen atom or a carboxyl protecting group (wherein when R.sup.2 contains quaternary ammonium, r.sup.2 and R.sup.3 may form a zwitter ion).The present invention also relates to the non-toxic and pharmaceutically acceptable salts of the cephalosporin compounds of the formula (I). Also described are compositions containing the antibiotics according to the present invention.